1. Home
  2. TYG vs KALV Comparison

TYG vs KALV Comparison

Compare TYG & KALV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Tortoise Energy Infrastructure Corporation

TYG

Tortoise Energy Infrastructure Corporation

HOLD

Current Price

$43.82

Market Cap

1.0B

Sector

Finance

ML Signal

HOLD

Logo KalVista Pharmaceuticals Inc.

KALV

KalVista Pharmaceuticals Inc.

HOLD

Current Price

$26.80

Market Cap

1.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TYG
KALV
Founded
2003
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.0B
1.0B
IPO Year
2003
2014

Fundamental Metrics

Financial Performance
Metric
TYG
KALV
Price
$43.82
$26.80
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$32.60
AVG Volume (30 Days)
167.8K
3.9M
Earning Date
05-04-2026
07-09-2026
Dividend Yield
11.71%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$50,000,000.00
Revenue This Year
N/A
$185.42
Revenue Next Year
N/A
$59.23
P/E Ratio
$52.62
N/A
Revenue Growth
N/A
495.66
52 Week Low
$40.28
$9.83
52 Week High
$51.18
$26.85

Technical Indicators

Market Signals
Indicator
TYG
KALV
Relative Strength Index (RSI) 30.12 74.29
Support Level $42.34 $14.22
Resistance Level $43.96 $26.85
Average True Range (ATR) 0.79 0.06
MACD -0.28 -0.28
Stochastic Oscillator 2.03 76.47

Price Performance

Historical Comparison
TYG
KALV

About TYG Tortoise Energy Infrastructure Corporation

Tortoise Energy Infrastructure Corp seeks to provide a high level of current income to stockholders. It invests in fixed-income and dividend-paying equity securities of power and energy infrastructure companies that provide stable and defensive characteristics throughout economic cycles.

About KALV KalVista Pharmaceuticals Inc.

KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.

Share on Social Networks: